Granules India Ltd.
NSE: GRANULES · Pharmaceuticals
Snapshot
Unlock Granules India Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Granules India Limited is a vertically integrated pharmaceutical company that manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages. The company serves a global market, providing products across diverse therapeutic categories including anti-retrovirals, analgesics, and oncology specialty products.
Business Model
The company operates on a vertically integrated model, controlling the value chain from API production to finished dosage forms. It generates revenue through the large-scale manufacturing and global distribution of pharmaceutical products to international markets.
Growth Outlook
Growth is driven by the expansion of its finished dosage portfolio and the strengthening of its global supply chain across North America, Europe, and emerging markets. The company continues to invest in specialty products, including oncology, to diversify its therapeutic offerings.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by international health authorities like the USFDA.
- Price Volatility. Intense competition in the generic pharmaceutical market can lead to pricing pressure and margin erosion for APIs and finished dosages.
- Supply Chain Disruptions. Dependency on global logistics and raw material sourcing makes the company vulnerable to geopolitical tensions and international trade disruptions.
- Currency Fluctuations. As a significant exporter, the company is exposed to foreign exchange risks that can impact profitability when reporting in Indian Rupees.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Granules India Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹5,366 Cr
TTM · consolidated
NET PROFIT
₹595 Cr
TTM · consolidated
EPS
₹24.44
TTM · consolidated
RETURN ON EQUITY
14.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
19.6%
TTM · consolidated
P/E
37.0x
Q4 FY26 · consolidated
EV/EBITDA
19.0x
Q4 FY26 · consolidated
EBITDA MARGIN
22.5%
TTM · consolidated
NET PROFIT MARGIN
13.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Granules India Ltd.GRANULES | 14,432 | 36.96 | 18.95 | 19.7% | 22.5% | 14.7% | 19.6% | +80.8% |
Neuland Laboratories Ltd.NEULANDLAB | 15,427 | 66.09 | 39.98 | 37.0% | 29.9% | 22.6% | 27.9% | +30.4% |
Onesource Specialty Pharma Ltd.ONESOURCE | 14,946 | 182.43 | 38.38 | — | 69.9% | 2.3% | 4.5% | -16.4% |
Jubilant Pharmova Ltd.JUBLPHARMA | 13,858 | 40.58 | 13.67 | 14.4% | 16.0% | 6.1% | 7.4% | -14.6% |
Alembic Pharmaceuticals Ltd.APLLTD | 13,129 | 24.47 | 15.07 | 10.1% | 16.0% | 12.6% | 14.2% | -18.1% |
Rubicon ResearchRUBICON | 12,884 | — | — | — | 23.0% | — | — | — |
As of Q4 FY26
Financials
Granules India Ltd.
NSE: GRANULES · Pharmaceuticals
Snapshot
Unlock Granules India Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Granules India Limited is a vertically integrated pharmaceutical company that manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages. The company serves a global market, providing products across diverse therapeutic categories including anti-retrovirals, analgesics, and oncology specialty products.
Business Model
The company operates on a vertically integrated model, controlling the value chain from API production to finished dosage forms. It generates revenue through the large-scale manufacturing and global distribution of pharmaceutical products to international markets.
Growth Outlook
Growth is driven by the expansion of its finished dosage portfolio and the strengthening of its global supply chain across North America, Europe, and emerging markets. The company continues to invest in specialty products, including oncology, to diversify its therapeutic offerings.
Key Risks
- Regulatory Compliance. The company faces significant risks related to stringent quality standards and inspections by international health authorities like the USFDA.
- Price Volatility. Intense competition in the generic pharmaceutical market can lead to pricing pressure and margin erosion for APIs and finished dosages.
- Supply Chain Disruptions. Dependency on global logistics and raw material sourcing makes the company vulnerable to geopolitical tensions and international trade disruptions.
- Currency Fluctuations. As a significant exporter, the company is exposed to foreign exchange risks that can impact profitability when reporting in Indian Rupees.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Granules India Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹5,366 Cr
TTM · consolidated
NET PROFIT
₹595 Cr
TTM · consolidated
EPS
₹24.44
TTM · consolidated
RETURN ON EQUITY
14.7%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
19.6%
TTM · consolidated
P/E
37.0x
Q4 FY26 · consolidated
EV/EBITDA
19.0x
Q4 FY26 · consolidated
EBITDA MARGIN
22.5%
TTM · consolidated
NET PROFIT MARGIN
13.7%
Q4 FY26 · consolidated
DEBT TO EQUITY
0.3x
Q4 FY26 · consolidated
Peers · Pharmaceuticals
As of Q4 FY26